GEA
BEAM icon

Glen Eagle Advisors’s Beam Therapeutics BEAM Stock Holding History

Glen Eagle Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60
Closed -$5.22K – 949
2021
Q3 		$5.22K Sell
60
-60
-50% -$6.03K ﹤0.01% 813
2021
Q2 		$15.4K Hold
120
– – ﹤0.01% 607
2021
Q1 		$9.61K Hold
120
– – ﹤0.01% 676
2020
Q4 		$9.8K Buy
+120
New +$5.9K ﹤0.01% 643

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Glen Eagle Advisors's BEAM Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Beam Therapeutics (BEAM) in Q4 2021, closing a stake of 60 shares — an estimated $5.22K sold.

Glen Eagle Advisors first reported a position in BEAM in Q4 2020 and held it in 4 quarters. The position peaked at $15.4K in Q2 2021. 232 funds tracked by Wall St. Rank hold BEAM as of Q4 2021.

  • Glen Eagle Advisors reported no remaining Beam Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 60 Beam Therapeutics shares in Q4 2021, an estimated $5.22K.
  • Glen Eagle Advisors first reported a position in Beam Therapeutics in Q4 2020 and held it in 4 quarters.
  • Glen Eagle Advisors's Beam Therapeutics position peaked at $15.4K in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.